Recommendations for breast cancer surveillance for female survivors of childhood, adolescent, and young adult cancer given chest radiation: A report from the International Late Effects of Childhood Cancer Guideline Harmonization Group

The Lancet Oncology

Volumn 14, Issue 13, 2013, Pages

  Mulder, Renée L ^a   Kremer, Leontien C M ^a   Hudson, Melissa M ^b   Bhatia, Smita ^c   Landier, Wendy ^c   Levitt, Gill ^d   Constine, Louis S ^e   Wallace, W Hamish ^f   Van Leeuwen, Flora E ^g   Ronckers, Cécile M ^h   Henderson, Tara O ⁱ   Dwyer, Mary ^j   Skinner, Roderick ^k   Oeffinger, Kevin C ^l  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d Great Ormond Street Hospital for Children NHS Trust Foundation ^*  (United Kingdom)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^g NETHERLANDS CANCER INSTITUTE   (Netherlands)

^h Dutch Childhood Oncology Group Longterm effects after childhood cancer (DOCG LATER)   (Netherlands)

ⁱ UNIVERSITY OF CHICAGO   (United States)

^j PETER MACCALLUM CANCER CENTRE   (Australia)

^k Infectious Diseases Allergy   (United Kingdom)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE ANTIBIOTIC AGENT;

ABDOMINAL RADIOTHERAPY; ADJUVANT THERAPY; AGE DISTRIBUTION; APOPTOSIS; BREAST; BREAST CANCER; BREAST CELL; BREAST EXAMINATION; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CANCER SURVIVOR; CHEST RADIOTHERAPY; CHILDHOOD CANCER; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; DIAGNOSTIC VALUE; EVIDENCE BASED PRACTICE; FALSE POSITIVE RESULT; FOLLOW UP; GENE MUTATION; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; INFORMATION RETRIEVAL; INTERNATIONAL COOPERATION; INTRADUCTAL CARCINOMA; LIFE EXPECTANCY; LONG TERM CARE; MAMMOGRAPHY; MEDICAL SOCIETY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PARTIAL BODY RADIATION; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; RADIATION INJURY; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; TUMOR SUPPRESSOR GENE; WOMEN'S HEALTH;

ADOLESCENT; AGE FACTORS; BREAST NEOPLASMS; CHILD; EARLY DETECTION OF CANCER; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INTERDISCIPLINARY COMMUNICATION; INTERNATIONAL COOPERATION; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MASS SCREENING; NEOPLASMS; POPULATION SURVEILLANCE; RADIOTHERAPY; RISK ASSESSMENT; SURVIVORS; TIME FACTORS; YOUNG ADULT;

EID: 84888104791     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70303-6     Document Type: Review

References (82)

1. Curry HL, Parkes SE, Powell JE, Mann JR Caring for survivors of childhood cancers: the size of the problem. Eur J Cancer 2006, 42:501-508.
2. Gatta G, Zigon G, Capocaccia R, et al. Survival of European children and young adults with cancer diagnosed 1995-2002. Eur J Cancer 2009, 45:992-1005.
3. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2008 2011, National Cancer Institute, Bethesda, MD, USA, (accessed April 16, 2012). http://seer.cancer.gov/csr/1975_2010.
4. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006, 355:1572-1582.
5. Geenen MM, Cardous-Ubbink MC, Kremer LC, et al. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA 2007, 297:2705-2715.
6. Henderson TO, Amsterdam A, Bhatia S, et al. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med 2010, 152:444-455.
7. Begg CB, Haile RW, Borg A, et al. Variation of breast cancer risk among BRCA1/2 carriers. JAMA 2008, 299:194-201.
8. Easton DF, Ford D, Bishop DT Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995, 56:265-271.
9. Easton DF, Steele L, Fields P, et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet 1997, 61:120-128.
10. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998, 62:676-689.
11. Fay MP, Pfeiffer R, Cronin KA, Le C, Feuer EJ Age-conditional probabilities of developing cancer. Stat Med 2003, 22:1837-1848.
12. Fay MP Estimating age conditional probability of developing disease from surveillance data. Popul Health Metr 2004, 2:6.
13. Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thomson MA Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. BMJ 1998, 317:465-468. The Cochrane Effective Practice and Organization of Care Review Group.
14. Grimshaw JM, Russell IT Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet 1993, 342:1317-1322.
15. Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. BMJ 1999, 318:527-530.
16. Clinical practice guidelines we can trust 2011, Institute of Medicine, The National Academies Press, Washington, DC, USA.
17. Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers. Version 3.0, 2008 Children's Oncology Group, (accessed April 5, 2011). http://www.survivorshipguidelines.org/.
18. Richtlijn follow-up na kinderkanker meer dan 5 jaar na diagnose. SKION, Den Haag/Amsterdam, the Netherlands Dutch Childhood Oncology Group, (accessed April 5, 2011). http://www.skion.nl/bestanden/richtlijn_follow-up_na_kinderkanker_deel_1_boekje_met_aanbevelingen_1.pdf.
19. Long term follow up of survivors of childhood cancer. A national clinical guideline Scottish Intercollegiate Guidelines Network, (accessed April 5, 2011). http://www.sign.ac.uk/guidelines/fulltext/132/index.html.
20. Therapy based long term follow up practice statement United Kingdom Children's Cancer Study Group Late Effects Group, (accessed April 5, 2011). http://www.cclg.org.uk/treatment-research/guidelines.
21. Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 2004, 22:4979-4990.
22. Kremer LC, Mulder RL, Oeffinger KC, et al. A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Pediatr Blood Cancer 2013, 60:543-549.
23. Gibbons RJ, Smith S, Antman E American College of Cardiology/American Heart Association clinical practice guidelines: part I: where do they come from?. Circulation 2003, 107:2979-2986.
24. Grading quality of evidence and strength of recommendations. BMJ 2004, 32:1490-1494. GRADE Working Group.
25. van der Weijden T, Boivin A, Burgers J, Schunemann HJ, Elwyn G Clinical practice guidelines and patient decision aids. An inevitable relationship. J Clin Epidemiol 2012, 65:584-589.
26. Guibout C, Adjadj E, Rubino C, et al. Malignant breast tumors after radiotherapy for a first cancer during childhood. J Clin Oncol 2005, 23:197-204.
27. Inskip PD, Robison LL, Stovall M, et al. Radiation dose and breast cancer risk in the childhood cancer survivor study. J Clin Oncol 2009, 27:3901-3907.
28. Taylor AJ, Winter DL, Pritchard-Jones K, et al. Second primary neoplasms in survivors of Wilms' tumour-a population-based cohort study from the British Childhood Cancer Survivor Study. Int J Cancer 2008, 122:2085-2093.
29. Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003, 290:465-475.
30. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003, 95:971-980.
31. Friedman DL, Rovo A, Leisenring W, et al. Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party. Blood 2008, 111:939-944.
32. de Bruin ML, Sparidans J, Van't Veer MB, et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 2009, 27:4239-4246.
33. Travis LB, Hill D, Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005, 97:1428-1437.
34. Bhatia S, Yasui Y, Robison LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol 2003, 21:4386-4394.
35. Kenney LB, Yasui Y, Inskip PD, et al. Breast cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Intern Med 2004, 141:590-597.
36. Metayer C, Lynch CF, Clarke EA, et al. Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. J Clin Oncol 2000, 18:2435-2443.
37. Taylor AJ, Winter DL, Stiller CA, Murphy M, Hawkins MM Risk of breast cancer in female survivors of childhood Hodgkin's disease in Britain: a population-based study. Int J Cancer 2007, 120:384-391.
38. Wolden SL, Hancock SL, Carlson RW, Goffinet DR, Jeffrey SS, Hoppe RT Management of breast cancer after Hodgkin's disease. J Clin Oncol 2000, 18:765-772.
39. Diller L, Medeiros NC, Shaffer K, et al. Breast cancer screening in women previously treated for Hodgkin's disease: a prospective cohort study. J Clin Oncol 2002, 20:2085-2091.
40. Kwong A, Hancock SL, Bloom JR, et al. Mammographic screening in women at increased risk of breast cancer after treatment of Hodgkin's disease. Breast J 2008, 14:39-48.
41. Lee L, Pintilie M, Hodgson DC, Goss PE, Crump M Screening mammography for young women treated with supradiaphragmatic radiation for Hodgkin's lymphoma. Ann Oncol 2008, 19:62-67.
42. Dershaw DD, Yahalom J, Petrek JA Breast carcinoma in women previously treated for Hodgkin disease: mammographic evaluation. Radiology 1992, 184:421-423.
43. Howell SJ, Searle C, Goode V, et al. The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage. Br J Cancer 2009, 101:582-588.
44. Oestreicher N, Lehman CD, Seger DJ, Buist DS, White E The incremental contribution of clinical breast examination to invasive cancer detection in a mammography screening program. AJR Am J Roentgenol 2005, 184:428-432.
45. Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 1998, 338:1089-1096.
46. Bobo JK, Lee NC, Thames SF Findings from 752 081 clinical breast examinations reported to a national screening program from 1995 through 1998. J Natl Cancer Inst 2000, 92:971-976.
47. Elmore JG, Armstrong K, Lehman CD, Fletcher SW Screening for breast cancer. JAMA 2005, 293:1245-1256.
48. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004, 351:427-437.
49. Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004, 292:1317-1325.
50. Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 2008, 148:671-679.
51. Lord SJ, Lei W, Craft P, et al. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer 2007, 43:1905-1917.
52. Kriege M, Brekelmans CT, Obdeijn IM, et al. Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer. Breast Cancer Res Treat 2006, 100:109-119.
53. Sardanelli F, Podo F, Santoro F, et al. Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the high breast cancer risk Italian 1 study): final results. Invest Radiol 2011, 46:94-105.
54. Li CI, Nishi N, McDougall JA, et al. Relationship between radiation exposure and risk of second primary cancers among atomic bomb survivors. Cancer Res 2010, 70:7187-7198.
55. Preston DL, Mattsson A, Holmberg E, Shore R, Hildreth NG, Boice JD Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiat Res 2002, 158:220-235.
56. van Ravesteyn NT, Miglioretti DL, Stout NK, et al. Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk. Ann Intern Med 2012, 156:609-617.
57. Evidence-based richtlijn mammacarcinoom, version 2.0 National Breast Cancer Organization Netherlands, (accessed April 5, 2011). http://www.oncoline.nl/richtlijn/item/index.php?pagina=/richtlijn/item/pagina.php&richtlijn_id=885.
58. Cutuli B, Borel C, Dhermain F, et al. Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases. Radiother Oncol 2001, 59:247-255.
59. Elkin EB, Klem ML, Gonzales AM, et al. Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin's lymphoma: a multi-institutional, matched cohort study. J Clin Oncol 2011, 29:2466-2473.
60. Janov AJ, Tulecke M, O'Neill A, et al. Clinical and pathologic features of breast cancers in women treated for Hodgkin's disease: a case-control study. Breast J 2001, 7:46-52.
61. Sanna G, Lorizzo K, Rotmensz N, et al. Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors. Ann Oncol 2007, 18:288-292.
62. Yahalom J, Petrek JA, Biddinger PW, et al. Breast cancer in patients irradiated for Hodgkin's disease: a clinical and pathologic analysis of 45 events in 37 patients. J Clin Oncol 1992, 10:1674-1681.
63. Warner E Clinical practice. Breast-cancer screening. N Engl J Med 2011, 365:1025-1032.
64. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L Screening for breast cancer: an update for the US Preventive Services Task Force. Ann Intern Med 2009, 151:727-742.
65. Fenton JJ, Barton MB, Geiger AM, et al. Screening clinical breast examination: how often does it miss lethal breast cancer?. J Natl Cancer Inst Monogr 2005, 35:67-71.
66. de Koning HJ Mammographic screening: evidence from randomised controlled trials. Ann Oncol 2003, 14:1185-1189.
67. Fracheboud J, Otto SJ, van Dijck JA, Broeders MJ, Verbeek AL, de Koning HJ Decreased rates of advanced breast cancer due to mammography screening in the Netherlands. Br J Cancer 2004, 91:861-867.
68. Groenewoud JH, Otten JD, Fracheboud J, et al. Cost-effectiveness of different reading and referral strategies in mammography screening in the Netherlands. Breast Cancer Res Treat 2007, 102:211-218.
69. Otto SJ, Fracheboud J, Looman CW, et al. Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet 2003, 361:1411-1417.
70. Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005, 365:1769-1778.
71. Bijker N, Peterse JL, Duchateau L, et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 2001, 19:2263-2271.
72. Tunon-de-Lara C, Lemanski C, Cohen-Solal-Le-Nir C, et al. Ductal carcinoma in situ of the breast in younger women: a subgroup of patients at high risk. Eur J Surg Oncol 2010, 36:1165-1171.
73. Virnig BA, Tuttle TM, Shamliyan T, Kane RL Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst 2010, 102:170-178.
74. The benefits and harms of breast cancer screening: an independent review. Lancet 2012, 380:1778-1786. Independent UK Panel on Breast Cancer Screening.
75. Berrington de Gonzalez A, Berg CD, Visvanathan K, Robson M Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers. J Natl Cancer Inst 2009, 101:205-209.
76. Trends in mammography dose and image quality 1974-2005 US Food and Drug Administration, Center for Devices and Radiological HealthCenter for Devices and Radiological Health, (accessed April 4, 2012). http://www.fda.gov/Radiation-EmittingProducts/MammographyQualityStandardsActandProgram/FacilityScorecard/ucm113352.htm.
77. Young KC, Burch A, Oduko JM Radiation doses received in the UK Breast Screening Programme in 2001 and 2002. Br J Radiol 2005, 78:207-218.
78. Griebsch I, Brown J, Boggis C, et al. Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer. Br J Cancer 2006, 95:801-810.
79. Norman RP, Evans DG, Easton DF, Young KC The cost-utility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30-49. Eur J Health Econ 2007, 8:137-144.
80. Plevritis SK, Kurian AW, Sigal BM, et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 2006, 295:2374-2384.
81. Taneja C, Edelsberg J, Weycker D, Guo A, Oster G, Weinreb J Cost effectiveness of breast cancer screening with contrast-enhanced MRI in high-risk women. J Am Coll Radiol 2009, 6:171-179.
82. Pijpe A, Andrieu N, Easton DF, et al. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ 2012, 345:e5660.